

# Marcello Maugeri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8276461/publications.pdf>

Version: 2024-02-01

94  
papers

3,338  
citations

172207

29  
h-index

168136

53  
g-index

94  
all docs

94  
docs citations

94  
times ranked

5964  
citing authors

#	ARTICLE	IF	CITATIONS
1	TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. <i>Oncogene</i> , 2015, 34, 681-690.	2.6	287
2	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. <i>Oncogene</i> , 2011, 30, 4231-4242.	2.6	221
3	Cancer Stem Cells and Chemosensitivity. <i>Clinical Cancer Research</i> , 2011, 17, 4942-4947.	3.2	181
4	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. <i>Cell Death and Differentiation</i> , 2012, 19, 768-778.	5.0	157
5	DNA Damage Repair Pathways in Cancer Stem Cells. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1627-1636.	1.9	147
6	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. <i>Annals of Oncology</i> , 2020, 31, 1746-1754.	0.6	140
7	The Hippo pathway in normal development and cancer. , 2018, 186, 60-72.		134
8	Metabolic features of cancer stem cells: the emerging role of lipid metabolism. <i>Oncogene</i> , 2018, 37, 2367-2378.	2.6	101
9	BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. <i>Oncogene</i> , 2013, 32, 1843-1853.	2.6	94
10	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	3.4	83
11	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016, 15, 1327-1336.	2.0	79
12	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e14.	1.6	75
13	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 318.	3.5	66
14	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. <i>Gut</i> , 2018, 67, 903-917.	6.1	64
15	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
16	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1924-1934.	0.5	60
17	SCD1, autophagy and cancer: implications for therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 265.	3.5	57
18	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	0.8	53

#	ARTICLE	IF	CITATIONS
19	Emerging Biological Treatments for Uterine Cervical Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 86-97.	1.2	51
20	Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. <i>Cancer Treatment Reviews</i> , 2013, 39, 525-533.	3.4	50
21	Hippo pathway and breast cancer stem cells. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 115-122.	2.0	48
22	Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>PLoS ONE</i> , 2013, 8, e69269.	1.1	45
23	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. <i>The RETROHER study. Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	1.1	39
24	MicroRNAs and Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 253-261.	1.0	35
25	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014, 5, 9619-9625.	0.8	35
26	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016, 7, 43188-43198.	0.8	35
27	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	2.0	33
28	“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33
29	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 119-123.	1.1	32
30	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 53.	6.9	32
31	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	3.5	32
32	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	2.1	30
33	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	2.3	30
34	A multicenter RETrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. <i>RePer Study. Cancer Biology and Therapy</i> , 2019, 20, 192-200.	1.5	30
35	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2065-2077.	0.5	28
36	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 62.	3.5	24
38	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 67.	3.5	22
39	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	1.5	22
40	Therapeutic Targeting of Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2011, 1, 10.	1.3	22
41	KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub. <i>Journal of Thoracic Oncology</i> , 2022, 17, 751-757.	0.5	21
42	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 718-724.	2.7	20
43	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	1.1	19
44	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. <i>Cell Death and Differentiation</i> , 2021, 28, 2060-2082.	5.0	19
45	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015, 368, 20-25.	3.2	17
46	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	2.0	17
47	Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1351-1361.	0.9	16
48	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	1.6	16
49	A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	2.0	16
50	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	1.8	16
51	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	1.0	16
52	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 49.	3.5	15
53	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 26.	3.5	15
54	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017, 7, 8078.	1.6	14

#	ARTICLE	IF	CITATIONS
55	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 111.	3.5	14
56	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	0.8	14
57	Cancer stem cells: are they responsible for treatment failure?. <i>Future Oncology</i> , 2014, 10, 2033-2044.	1.1	13
58	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	3.4	13
59	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	1.8	13
60	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13
61	Biological and clinical implications of cancer stem cells in primary brain tumors. <i>Frontiers in Oncology</i> , 2013, 3, 6.	1.3	12
62	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	2.0	12
63	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016, 231, 986-991.	2.0	12
64	Body mass index modifies the relationship between $\gamma$ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	1.1	12
65	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	1.5	12
66	Deep sequencing and pathway-focused analysis revealed multigene oncogene signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	2.1	12
67	A cut-off of 2150 cytokeratin 19 mRNA copy number in sentinel lymph node may be a powerful predictor of non-sentinel lymph node status in breast cancer patients. <i>PLoS ONE</i> , 2017, 12, e0171517.	1.1	12
68	Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real world setting. <i>Oncotarget</i> , 2017, 8, 69025-69037.	0.8	12
69	The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	2.1	11
70	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	1.1	11
71	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	0.8	11
72	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 2246-2252.	2.0	9
74	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	1.6	8
75	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
76	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1381-1397.	2.5	6
77	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016, 6, 35121.	1.6	6
78	Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45Åy or younger: Evidence from a historic cohort. <i>Cancer Biology and Therapy</i> , 2016, 17, 470-476.	1.5	6
79	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 247.	1.8	6
80	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
81	Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. <i>Journal of Cellular Physiology</i> , 2015, 230, 1708-1712.	2.0	5
82	Functional Role of MicroRNAs in Prostate Cancer and Therapeutic Opportunities. <i>Critical Reviews in Oncogenesis</i> , 2013, 18, 303-316.	0.2	5
83	Hot flushes in women with breast cancer: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 185-198.	1.1	4
84	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	1.2	4
85	ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. <i>Future Oncology</i> , 2017, 13, 1517-1525.	1.1	4
86	Translating basic research in cancer patient care. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2011, 47, 64-71.	0.2	4
87	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	2
88	Approaching the Increasing Complexity of Non-small Cell Lung Cancer Taxonomy. <i>Current Pharmaceutical Design</i> , 2014, 20, 3973-3981.	0.9	2
89	KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2" Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis". <i>Journal of Thoracic Oncology</i> , 2020, 15, e87-e88.	0.5	1
90	Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e199.	1.7	1

#	ARTICLE	IF	CITATIONS
91	KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously" Journal of Thoracic Oncology, 2022, 17, e40-e41.	0.5	1
92	Targeting Self-renewal Pathways in Cancer Stem Cells. , 2012, , 25-36.		0
93	Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study. Annals of Oncology, 2015, 26, vi13.	0.6	0
94	Abstract SY01-02: Targeting stem cell pathways in human cancer. , 2016, , .		0